Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron M Goodman

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|March 28, 2019
Immune Escape of AML Cells after TransplantationAaron M Goodman, Razelle Kurzrock
Blood|April 24, 2020
An IgA plasmacytoma: a rare and distinct form of plasmacytomaHuan-You Wang, Aaron M Goodman
Nature Reviews. Clinical Oncology|April 22, 2024
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trialsGhulam Rehman Mohyuddin, Aaron M Goodman
European Journal of Cancer (Oxford, England : 1990)|March 30, 2023
Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populationsGhulam Rehman Mohyuddin, Aaron M Goodman
Nature Reviews. Clinical Oncology|August 13, 2021
Practicing on the edge of oncology: when standard of care feels uncomfortableChristopher M Booth, Aaron M Goodman
Nature Reviews. Clinical Oncology|May 29, 2025
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trialsGhulam Rehman Mohyuddin, Aaron M Goodman
European Journal of Cancer (Oxford, England : 1990)|September 21, 2021
Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concernGhulam Rehman Mohyuddin, Rahul Banerjee, Aaron M Goodman
The Oncologist|February 12, 2020
Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester DiseaseIla M Saunders, Aaron M Goodman, Razelle Kurzrock
Ejhaem|January 21, 2026
Refractory Periorbital Necrobiotic Xanthogranuloma Treated With Plasma Cell-Directed TherapyAaron Trando, Ah-Reum Jeong, Aaron M Goodman
The Oncologist|July 17, 2025
Contextualizing results of randomized trials in smoldering myelomaGhulam Rehman Mohyuddin, Aaron M Goodman, Rajshekhar Chakraborty
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|March 28, 2019
Immune Escape of AML Cells after TransplantationAaron M Goodman, Razelle Kurzrock
Blood|April 24, 2020
An IgA plasmacytoma: a rare and distinct form of plasmacytomaHuan-You Wang, Aaron M Goodman
Nature Reviews. Clinical Oncology|April 22, 2024
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trialsGhulam Rehman Mohyuddin, Aaron M Goodman
European Journal of Cancer (Oxford, England : 1990)|March 30, 2023
Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populationsGhulam Rehman Mohyuddin, Aaron M Goodman
Nature Reviews. Clinical Oncology|August 13, 2021
Practicing on the edge of oncology: when standard of care feels uncomfortableChristopher M Booth, Aaron M Goodman
Nature Reviews. Clinical Oncology|May 29, 2025
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trialsGhulam Rehman Mohyuddin, Aaron M Goodman
European Journal of Cancer (Oxford, England : 1990)|September 21, 2021
Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concernGhulam Rehman Mohyuddin, Rahul Banerjee, Aaron M Goodman
The Oncologist|February 12, 2020
Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester DiseaseIla M Saunders, Aaron M Goodman, Razelle Kurzrock
Ejhaem|January 21, 2026
Refractory Periorbital Necrobiotic Xanthogranuloma Treated With Plasma Cell-Directed TherapyAaron Trando, Ah-Reum Jeong, Aaron M Goodman
The Oncologist|July 17, 2025
Contextualizing results of randomized trials in smoldering myelomaGhulam Rehman Mohyuddin, Aaron M Goodman, Rajshekhar Chakraborty
Pageof 8